Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.

Duchenne muscular dystrophy (DMD) is a fatal disease caused by defects in the gene encoding dystrophin. Dystrophin is a cytoskeletal protein, which together with its associated protein complex, helps to protect the sarcolemma from mechanical stresses associated with muscle contraction. Gene therapy efforts aimed at supplying a normal dystrophin gene to DMD muscles could be hampered by host immune system recognition of dystrophin as a "foreign" protein. In contrast, a closely related protein called utrophin is not foreign to DMD patients and is able to compensate for dystrophin deficiency when overexpressed throughout development in transgenic mice. However, the issue of which of the two candidate molecules is superior for DMD therapy has remained an open question. In this study, dystrophin and utrophin gene transfer effects on dystrophic muscle function were directly compared in the murine (mdx) model of DMD using E1/E3-deleted adenovirus vectors containing either a dystrophin (AdV-Dys) or a utrophin (AdV-Utr) transgene. In immunologically immature neonatal animals, AdV-Dys and AdV-Utr improved tibialis anterior muscle histopathology, force-generating capacity, and the ability to resist injury caused by high-stress contractions to an equivalent degree. By contrast, only AdV-Utr was able to achieve significant improvement in force generation and the ability to resist stress-induced injury in the soleus muscle of immunocompetent mature mdx animals. In addition, in mature mdx mice, there was significantly greater transgene persistence and reduced inflammation with utrophin compared to dystrophin gene transfer. We conclude that dystrophin and utrophin are largely equivalent in their intrinsic abilities to prevent the development of muscle necrosis and weakness when expressed in neonatal mdx animals with an immature immune system. However, because immunity against dystrophin places an important limitation on the efficacy of dystrophin gene replacement in an immunocompetent mature host, the use of utrophin as an alternative to dystrophin gene transfer in this setting appears to offer a significant therapeutic advantage.

[1]  R. Mulligan,et al.  Dystrophin expression in the mdx mouse restored by stem cell transplantation , 1999, Nature.

[2]  P. McCray,et al.  Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of lipopolysaccharide-induced inflammation. , 1999, American journal of respiratory cell and molecular biology.

[3]  K. Davies,et al.  Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. , 1999, Human gene therapy.

[4]  T. Libermann,et al.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.

[5]  S. Kochanek,et al.  DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. , 1999, Human gene therapy.

[6]  J. Nalbantoglu,et al.  Combinatorial Blockade of Calcineurin and CD28 Signaling Facilitates Primary and Secondary Therapeutic Gene Transfer by Adenovirus Vectors in Dystrophic (mdx) Mouse Muscles , 1998, Journal of Virology.

[7]  K. Okumura,et al.  Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implication for gene therapy. , 1998, Journal of immunology.

[8]  K. Campbell,et al.  Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using delta-sarcoglycan gene transfer. , 1998, Molecular cell.

[9]  Hanns Lochmüller,et al.  Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice , 1998, Gene Therapy.

[10]  K. Davies,et al.  Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle. , 1998, Biochemical and biophysical research communications.

[11]  K. Davies,et al.  Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice , 1997, Nature Medicine.

[12]  Susan C. Brown,et al.  Utrophin-Dystrophin-Deficient Mice as a Model for Duchenne Muscular Dystrophy , 1997, Cell.

[13]  J. Sanes,et al.  Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy , 1997, Cell.

[14]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[15]  A. Beaudet,et al.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. , 1997, Human gene therapy.

[16]  K. Davies,et al.  Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene , 1996, Nature.

[17]  J. Wilson,et al.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. , 1996, Human molecular genetics.

[18]  R. Balice-Gordon,et al.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. , 1996, Human gene therapy.

[19]  Hanns Lochmüller,et al.  Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T cell deficiency. , 1996, Human gene therapy.

[20]  J. Leiden,et al.  Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.

[21]  Hanns Lochmüller,et al.  Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. , 1996, Human gene therapy.

[22]  R. Worton.  Muscular Dystrophies—Diseases of the Dystrophin-Glycoprotein Complex , 1995, Science.

[23]  I. Kinoshita,et al.  Successful histocompatible myoblast transplantation in dystrophin- deficient mdx mouse despite the production of antibodies against dystrophin , 1995, The Journal of cell biology.

[24]  C. Gravel,et al.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.

[25]  Hanns Lochmüller,et al.  Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. , 1995, American journal of respiratory cell and molecular biology.

[26]  G. Splitter,et al.  Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. , 1995, Human gene therapy.

[27]  W. Kress,et al.  Serum antibodies to the deleted dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy. , 1995, The New England journal of medicine.

[28]  S. Winder,et al.  Calcium/calmodulin‐dependent regulation of the NH2‐terminal F‐actin binding domain of utrophin , 1995, FEBS letters.

[29]  Hanns Lochmüller,et al.  Emergence of Early Region 1-Containing Replication-Competent Adenovirus in Stocks of Replication-Defective Adenovirus Recombinants (ΔE1 + ΔE3) During Multiple Passages in 293 Cells , 1994 .

[30]  R. Edwards,et al.  Time course of changes in plasma membrane permeability in the dystrophin‐deficient mdx mouse , 1994, Muscle & nerve.

[31]  K. Campbell,et al.  Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. , 1994, Human molecular genetics.

[32]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Armstrong,et al.  Mechanical factors in the initiation of eccentric contraction‐induced injury in rat soleus muscle. , 1993, The Journal of physiology.

[34]  H. Sweeney,et al.  Dystrophin protects the sarcolemma from stresses developed during muscle contraction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Davies,et al.  Localization and Quantitation of the Chromosome 6-Encoded Dystrophin-Related Protein in Normal and Pathological Human Muscle , 1993, Journal of neuropathology and experimental neurology.

[36]  K. Davies,et al.  The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies , 1992, Neuromuscular Disorders.

[37]  P. Wilcox,et al.  Monocyte inflammatory mediators impair in vitro hamster diaphragm contractility. , 1992, The American review of respiratory disease.

[38]  O. Ibraghimov-Beskrovnaya,et al.  Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix , 1992, Nature.

[39]  Simon C Watkins,et al.  Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle , 1991, Neuromuscular Disorders.

[40]  K. Davies,et al.  Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines , 1991, The Journal of cell biology.

[41]  J. Shrager,et al.  The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy , 1991, Nature.

[42]  Simon C Watkins,et al.  Somatic reversion/suppression of the mouse mdx phenotype in vivo , 1990, Journal of the Neurological Sciences.

[43]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[44]  J. E. Anderson,et al.  Electron microscopic and autoradiographic characterization of hindlimb muscle regeneration in the mdx mouse , 1987, The Anatomical record.

[45]  J. Tidball,et al.  Energy stored and dissipated in skeletal muscle basement membranes during sinusoidal oscillations. , 1986, Biophysical journal.

[46]  P. Medawar,et al.  ‘Actively Acquired Tolerance’ of Foreign Cells , 1953, Nature.